CN101720937A - Nutriment containing phosphorus, vanadium, molybdenum and tungsten - Google Patents
Nutriment containing phosphorus, vanadium, molybdenum and tungsten Download PDFInfo
- Publication number
- CN101720937A CN101720937A CN200910214447A CN200910214447A CN101720937A CN 101720937 A CN101720937 A CN 101720937A CN 200910214447 A CN200910214447 A CN 200910214447A CN 200910214447 A CN200910214447 A CN 200910214447A CN 101720937 A CN101720937 A CN 101720937A
- Authority
- CN
- China
- Prior art keywords
- vanadium
- molybdenum
- compound
- tungsten
- valence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a nutriment which contains phosphorus, vanadium, molybdenum, tungsten, a mixture containing a phosphorus-contained compound, a vanadium-contained compound, a molybdenum-contained compound and a tungsten-contained compound or heteropolyacid and salts thereof which are formed by oxyacid containing phosphorus, vanadium, molybdenum, tungsten and salts thereof. The phosphorus-contained compound is phosphoric acid of +5 valence or phosphorus-contained water soluble salt; the vanadium-contained compound is a water soluble compound or complex of vanadium of +5 valence, +4 valence, +3 valence and +2 valence or heteropolyacid or heteropoly acid salt formed by the vanadium and other elements; the molybdenum-contained compound is a water soluble compound or complex of the molybdenum of +6 valence, +5 valence and +4 valence or heteropolyacid or heteropoly acid salt formed by the molybdenum and other elements; the tungsten-contained compound is a water soluble compound or complex of the tungsten of +6 valence, +5 valence and +4 valence or heteropolyacid or heteropoly acid salt formed by the tungsten and other elements. The nutriment has the effects of rapidly eliminating most of chemical substances having toxic and side effects on the human body and reducing the pathogenic factor, thereby directly prolonging the human life.
Description
Technical field
The present invention relates to the nutriment field, be specifically related to a kind of nutriment of phosphorous vanadium, molybdenum and tungsten.
Background technology
At present, a large amount of micro-vanadium that studies show that have the effect of insulin mimetic effect in human body, it can reduce the effect of blood sugar in I, the II type diabetes human body effectively, but its toxic and side effect is bigger, surpass under the oral once used amount situation of 5mg/ as the oral positive vanadic acid of healthy population, metavanadic acid and its esters, human body can begin to produce the diarrhoea effect in 1～4 hour, and body begins to run off and causes Na
+, K
+The unbalanced side effect of ion.
In order to solve above-mentioned side effect, the way that existing microelement-supplementing vanadium technology adopts synthetic biguanides vanudium complex, lutidines acid vanadyl complex, two (2-methyl-3-hydroxyl-pyrokomane) to close the vanudium complex of vanadyl (IV), pyridinedicarboxylic acid vanadyl complex, two benzoglycolic acid pyridine vanadium (V), diamylose bud phenols vanudium complex, monohydroxamates is mostly replenished vanadium to the diabetes patient, and the someone utilizes the way of Transdermal absorption to avoid the side effect of oral absorption even.But, after above-mentioned way can't solve the vanadic acid radical ion and enters back in the body, particularly enters in the cell, vanadic acid root and its esters be to the inhibition of numerous biological enzymes and activation and the biological metabolism imbalance problem that causes, thereby limited the effective utilization of vanadium ion to human body beneficial's factor.
Molybdenum is the human body trace elements necessary of having confirmed at present, and the molybdenum dietary intake value that WHO recommends is 2 μ g/kg body weight, and NOAEL is 350 μ g.The report of human molybdenosis is few, high molybdenum area soil contains molybdenum 77mg in state of Republic of Armenia, copper 59mg, the resident molybdenum 10～15mg that takes food average every day, copper 5～10mg, and the take food every day amount of molybdenum copper of the average resident in check plot is respectively 1～2mg and 5～10mg, and 362 high molybdenum Qu Shoujian, 17 people that are grown up have the crazy symptom of comparatively typical pain, knee joint, articulations digitorum manus and refer to, a plurality of joint involvement such as toe, swelling, pain, regular outbreak and with deformity.The crowd of this area serum uric acid salt content and organize the activity of xanthine oxidase all to be higher than the check plot resident.
People and most of organism all need the confactor of molybdenum as plurality of enzymes, in biological oxidation-reduction, molybdenum mainly plays the electronics transfer function with the conversion between pentavalent and the sexavalence molybdenum, and it is the constituent of mammiferous 3 kinds of metallothioneins: xanthine oxidase, aldehyde oxidase and sulfide oxidation enzyme.Too much supply with molybdenum compound (except that slightly solubility molybdenum bisuphide etc.) at human body, it can improve cells in vivo, and all contain the oxidasic activity of molybdenum, wherein the raising of xanthine oxidase activity can cause the synthetic increase of interior uric acid of body and its esters, and then cause increasing that the relevant disease of generation---the crazy and ill increase of lithuria calculus of pain has directly caused molybdenum can't be used for human body in a large number with uric acid.
The PCR was set up by the K.Mullis of U.S. Cetus company in nineteen eighty-three, and and the inventor M.Smith of rite-directed mutagenesis win 1993 annual Nobel chemistry Prizes together, for the brand-new epoch have been started in the research of life science.Participate in the Main Ingredients and Appearance of polymerase chain PCR reaction: template, primer, dNTP, Taq archaeal dna polymerase and buffer solution etc.Wherein template be can genomic DNA, RNA, DNA, mitochondrial DNA etc., primer is the oligonucleotide fragment of chemical synthesis.Deoxynucleoside triphosphate (dNTP) is the mixture of dATP, dCTP, dGTP and dTTP4 kind deoxynucleoside triphosphate, archaeal dna polymerase is to live in aquatic the hot spring (80 ℃～90 ℃) and bite hot bacterium Thermus γ aquaticus from a kind of, Taq) extract in, the effect of very high heat-resistant stability Taq enzyme is arranged.
Existing PCR can't directly be used in the human body active somatic cell, it is because participate in the Main Ingredients and Appearance of PCR (PCR): template, primer, dNTP, Taq archaeal dna polymerase and buffer solution etc. can't enter in the human tissue cell simultaneously effectively, even being injected into them, we utilize cytogene to increase in the cell, immunological rejection with the Taq archaeal dna polymerase of human body gene non-homology, and other primer, dNTP, pair cells such as buffer solution also have imbalance problem toxic and side effect or that cause metabolism, and these have all limited the PCR can't directly be used in the human body active somatic cell.
Absorb in vivo in the food of humans and animals and contain some chemical substance generation in the conversion process usually the human body toxic side effect, corresponding chemical substance with toxic and side effect will be accumulated in vivo when the metabolism imbalance takes place human body, thereby produces corresponding harm.Such as the uremic patient that serious ephritis causes, modern medicine is except kidney transplantation or regularly carry out the haemodialysis better medical procedure not being arranged also at present.The present invention is by strengthening the powerful metabolic function of all cells self in the humans and animals body, and performance is more incomparable and have more the biochemistry metabolism effect of distinctive toxic and side effect than kidney transplantation and haemodialysis.
In view of this, the present invention is on the basis through a series of fundamental research and test, by human body being supplied with simultaneously four kinds of phosphorus vanadium, molybdenum and tungsten elements, utilize them to produce mutual restriction in human body metabolism's course of reaction and eliminate the harm to the human body unfavorable factor of vanadium, molybdenum, this case produces thus.
Summary of the invention
The object of the present invention is to provide a kind of nutriment of phosphorous vanadium, molybdenum and tungsten, by human body being supplied with simultaneously four kinds of phosphorus vanadium, molybdenum and tungsten elements, utilize them in human body metabolism's course of reaction, to produce mutual restriction and eliminate vanadium, molybdenum is to the harm of human body unfavorable factor, by they human body and zooblast intracellular metabolite facilitation obtain a kind of can quicken to eliminate to the most of chemical substances of organism toxic side effect in vivo accumulate method, obtain a kind of chemical method that promotes glucose metabolism generation ATP at cell interior simultaneously, obtain the chemical method that a kind of DNA of promotion → DNA cloning and DNA → RNA → protein and enzyme acceleration thereof are translated at cell interior simultaneously, simultaneously in cell interior obtains a kind of minimizing cell, intercellular neurotransmitter, hormone, the Chemical Inhibition factor of cell factor obtains main component oxalic acid in a kind of promotion stone in urinary system and the gall stone at cell interior simultaneously, the dissolving of uric acid and decomposition of salts thereof and phosphatic calculus, cystine in the cell, cholesterol, bile acid generates the chemical method that reduces.
To achieve these goals, solution of the present invention is as follows:
A kind of nutriment of phosphorous vanadium, molybdenum and tungsten is to contain the common mixture of forming of phosphorus-containing compound, vanadium-containing compound, molybdate compound and Tungstenic compound; Or contain heteropoly acid and its esters that phosphorus vanadium, molybdenum and tungsten oxyacid and its esters form each other.
Described phosphorus-containing compound is the phosphoric acid or the phosphorous water soluble salt of+5 valencys.
Described vanadium-containing compound is+5 ,+4 ,+3 ,+heteropoly acid or heteropolyacid salt that the water soluble compound of the vanadium of divalent attitude or complex compound or vanadium and other element form.
Described molybdate compound is+6 ,+5 ,+heteropoly acid or heteropolyacid salt that the water soluble compound of the molybdenum of 4 valence states or complex compound or molybdenum and other element form.
Described Tungstenic compound can be+6 ,+5 ,+heteropoly acid or heteropolyacid salt that the water soluble compound of the tungsten of 4 valence states or complex compound or tungsten and other element form.
The molecular number proportioning of each component of described vanadium-containing compound, phosphorus-containing compound, molybdate compound and Tungstenic compound is V: P: Mo: W=1: (6～12): (6～12): (8～16).
The molecular number proportioning of each component of described vanadium-containing compound, phosphorus-containing compound, molybdate compound and Tungstenic compound is V: P: Mo: W=1: 8.5: 8.5: 10.
Phosphorous P, vanadium V, molybdenum Mo, tungsten W mixture can be complex compound or heteropoly acid (salt) class that forms with other element.Use separately tungsten+6 ,+5 ,+all water soluble compounds of 4 common valence states, can remove the chemical action of the uric acid that the humans and animals cell interior produces effectively.+ 6 ,+5 ,+4 the molybdenum Mo compound of common valence state includes the oxidasic activity of molybdenum and causes cell uric acid synthetic quantity to increase by improving cell, increase the crazy illness of pain, the rheumatism incidence of disease, merge to use tungsten+6 ,+5 ,+all water soluble compounds of 4 common valence states can alleviate the illness generation relevant with uric acid by uricolytic effect.Phosphorus P, vanadium V, molybdenum Mo, tungsten W be in vivo after the metabolism, can suppress, dissolves or decompose the effect of main component oxalic acid in urinary calculi, the gall stone and its esters, uric acid and its esters, insoluble phosphate class, cystine, cholesterol, bile acid in vivo.
Phosphorus P, vanadium V, molybdenum Mo, tungsten W are in vivo after the metabolism, vanadium V compound has the effect that strengthens promotion glucose metabolism acquisition ATP in cell, the synthetic increase of ATP increases dATP, dCTP, dGTP and 4 kinds of deoxynucleoside triphosphate biosynthesis of dTTP, for DNA → DNA cloning, DNA → RNA translate, RNA → protein and enzyme are translated the guarantee on the energy is provided; Molybdenum compound is 3 kinds of metallothioneins---the constituent of xanthine oxidase, aldehyde oxidase and sulfide oxidation enzyme, increase the interior molybdenum content of body and can strengthen these oxidasic activity, the result helps the scavenging action of aldoketones, pyridine, thialdine, quinoline, purine, pyrazoles, pyrimidine, talk endlessly pyridine and other heterocyclic chemistry material in the cell, helps to reduce these chemical substances inhibitory action to DNA, RNA, range protein and enzyme in cell.Thus, vanadium V, molybdenum Mo merge to use jointly to DNA → DNA cloning, DNA → RNA translate, RNA → protein and enzyme translate and played collaborative facilitation.
In the cell, intercellular neurotransmitter, hormone, the cell factor overwhelming majority contain active uncle's ammonia R-NH, R-NH
2Group, the aldoketones chemical substance helps reducing the inhibitory action to them in the removing minimizing cell.Phosphorus P, vanadium V, molybdenum Mo, tungsten W are in vivo after the metabolism, vanadium V compound has the effect that strengthens promotion glucose metabolism acquisition ATP in cell, vanadium V compound also has the ketoplasia effect that suppresses hepatic tissue cell, to diabetes except that having blood sugar reducing function, can also remove the effect of unnecessary ketoboidies in the body, the ketone acid illness that is caused by diabetes is had remarkable therapeutic action.
Phosphorus P, vanadium V, molybdenum Mo, tungsten W be in vivo after the metabolism, and molybdenum Mo compound has and strengthens the effect that contains molybdenum oxidase subunit sulfuric acid oxidation enzymatic activity, main acid contaminant sulfur dioxide (SO in current air in cell
2) environmental pollution in, help humans and animals to the acid contaminant sulfur dioxide (SO in the suction body
2) the biochemistry scavenging action.
The invention has the beneficial effects as follows: can make with phosphorous vanadium, molybdenum and tungsten oxyacid and its esters with a kind of, the manufacture process method is very simple, also can select the compound of the multiple valence state of phosphorus vanadium, molybdenum and tungsten to make, and makes the raw material source extensively.This nutriment has quicken to be eliminated the most of chemical substances of human body toxic side effect accumulating (comprising the chemical substance to the human body toxic side effect that most of bacteriums and viral metabolism produce) in vivo, reduce common paathogenic factor, thereby have the effect of direct prolongation human longevity.
The specific embodiment
(1) proportioning of P, V, Mo, W
P, V, Mo, W mainly in human body cell by after a series of biochemistry metabolism, its final stable chemical substance is brought into play synergy in vivo in the humans and animals body, so when concrete prescription, only need these four kinds or wherein two kinds, three kinds of units have certain atomicity proportioning and can bring into play relevant biological chemistry action discussed above, vanadate with+5 valencys, the phosphate of+5 valencys, the molybdate of+6 valencys, the molecular number proportioning V of the tungstates of+6 valencys: P: Mo: W=1: (6～12): (6～12): when (8～16), synergistic action effect is obvious each other; Wherein with V: P: Mo: W=1: be optimum at 8.5: 8.5: 10, and general Mo: W≤1 in the prescription is with the tungsten that the guarantees q.s removing amount with uric acid that molybdenum is caused.
But require said ratio can do following adjustment at different patients, to urinary calculus be diagnosed as phosphoric acid salt calculus time+5 valency vanadate ,+phosphate of 5 valencys ,+molybdate of 6 valencys ,+the molecular number proportioning V of the tungstates of 6 valencys: P: Mo: W=1: (0～6): 8.5: 10 for optimum, to the vanadate of pain crazy illness+5 valencys ,+phosphate of 5 valencys ,+molybdate of 6 valencys ,+the molecular number proportioning V of the tungstates of 6 valencys: P: Mo: W=1: 8.5: (0～6): 10 be optimum; If with contain that V, P, Mo, W generate have the heteropoly acid of certain atomicity proportioning the time, its molecular number proportioning optimum can be V: P: Mo: W=1: (6～12): (6～12): (8～16), if wherein a certain element proportioning can't reach fixed mixing ratio and count V: P: Mo: W=1: (6～12): (6～12): when (8～16), can add this element compound to above-mentioned ratio separately and get final product, heteropoly acid can comprise other element.In addition, if when needing with the element of other valence state or the replacement of multiple valence state compound, only need these atoms of elements to count greatly most V of ratio: P: Mo: W=1: proportioning got final product in 8.5: 8.5: 10, because P, V, Mo, W element have certain checkout time in vivo, certain effect is roughly the same mutually arranged so separately use with the merging use in a period of time (in a week).
If two kinds of set of dispense of above-mentioned need than the time, in the following several ways:
(a)V-P＝1∶17；(b)V-Mo＝1∶17；(c)V∶W＝1∶17
(d)P∶Mo＝1∶1；(e)P∶W＝1∶1.2；(f)Mo∶W＝1∶1.2
If three kinds of proportionings, in the following several ways:
(a)V∶P∶Mo＝1∶8.5∶8.5；(b)V∶Mo∶W＝1∶8.5∶10；(c)P∶Mo∶W＝1∶1∶1.2
Above ratio might not extremely strictly observe, in the prescription that contains v element based on the vanadium overall control, as two kinds of set of dispense than the time V: P, V: Mo, V: the W proportioning is 1: (12～24) also are acceptable; So can analogize the proportioning of three kinds of element mixture.
(2) safety using amount
(1) requirement of phosphorus and toxic dose
It is 3000 milligrams of every days that phosphorus the highest tolerates the intake children, and per day for adults is 3500 milligrams, and Chinese take in 1057.8 milligrams of phosphorus every day from meals, some additional dosage such as 2000mg/d also can not surpass the highest intake that tolerates even if the adult adds.Become human body to include the about 700～800g of phosphorus, about 85% is present in the bone.All the other are present in the soft tissue with the organophosphorous ester form.Phosphorous only 2g in the extracellular fluid, the normal serum phosphorus concentration is 0.8～1.3mmol/L.
(2) requirement of vanadium and toxic dose
According to U.S. food and nutrient research meeting (Food and Nutrition Board) report, the dosage (NOAEL) that vanadium is not observed ill-effect is 0.8mg/ (kgd), and observed minimum ill-effect dosage (LOAEL) is 7.7mg/ (kgd).That estimates allows that taking in the upper limit (UL) is calculated as follows:
UL=LOAEL/UF (uncertain coefficient)
＝7.7mg/(kg·d)/300＝0.026mg/(kg·d)
Vanadium is the bigger element of a kind of toxicity, and its toxicity increases with valent rising, with V
2O
5, and other 5 valency vanadic salts toxicity maximums.Usually add with the vanadate form, according to estimates, add 50～500 μ g/kg vanadium in the feed diet that isozygotys and to satisfy the minimum growth needs of animal.The level of security of vanadium is 5mg/kg in the chick daily ration, and laying hen is 10mg/kg.When vanadium reaches 30mg/kg in the little daily grain of chicken, can make growth retardation, 200mg/kg causes mortality.Sheep is strong slightly to the vanadium tolerance, and the content of daily ration vanadium can be increased to 20mg/kg.When the ammonium vanadate of the 400mg/kg body weight of feeding, dead behind the 80h.After adding the vanadite of 800mg/kg body weight in the feed of sheep, sheep stops to search for food, and symptom of diarrhea is arranged behind the 1d, and the symptom that stops to feed promptly disappears.Data shows that ruminants such as cattle and sheep can reach 50mg/kg to the dosis tolerata of vanadium.
The inventor is through using metavanadic acid ammonia in human trial separately, and observed result is that minimum ill-effect dosage is 5mg/ single oral consumption (50kg body weight), or 3 * 2.5mg/ (the single oral consumption is on average every 4 hours) (50kg body weight).Surpass above-mentioned dosage and will cause diarrhoea to human body is oral, diarrhoea occurs in behind the oral medication 1～4 hour, brings electrolytical metabolism imbalance in the human body thus.
After P, V, Mo, the use of W element oxyacid mixture, mixing the observed result of use metavanadic acid ammonia is that minimum ill-effect dosage is 14mg/ single oral consumption (50kg body weight), or 3 * 10mg/ (the single oral consumption is on average every 4 hours) (50kg body weight).Surpass above-mentioned dosage and will cause diarrhoea human body is oral, bring the metabolism imbalance of cylinder electrolyte, this shows that the method for using mixture makes minimum ill-effect dosage by original using dosage 5mg/ single oral consumption (50kg body weight) separately, bring up to 14mg/ single oral consumption (50kg body weight), improved 2.8～4 times.
The method that utilize to generate the vanadate complex compound also can meet or exceed 14mg/ single oral consumption (50kg body weight) and not produce the diarrhoea effect, but the ligand complex ion of complex compound is after metabolism is decomposed in vivo, just not to free vanadic acid radical ion VO
4 3-Inhibitory action (except the intrinsic phosphoric acid of cells in vivo and its esters to free vanadic acid radical ion VO
4 3-Complexing outer), whenever other blending ingredients all can be to free vanadic acid radical ion VO in human body and adopt the present invention
4 3-Having with the dehydration condensation is reaction feature, that form heteropoly acid.So the present invention adopts other any technology can't reach in cell thoroughly to solve vanadic acid radical ion VO at present
4 3-Side-effect problem, the present invention can thoroughly solve vanadic acid radical ion VO inside and outside cell in vivo
4 3-The cellular metabolism imbalance problem that the inhibition and the activation of most of enzymes caused.
Adopt the present invention can reduce the toxic side effects of vfanadium compound in the humans and animals body, also can improve the tolerance dose of humans and animals simultaneously vanadium.In addition; adopt P, Mo, the W mixing formula of no vanadium to merge vitamin C to heavy dose of vanadiumism and have therapeutic action preferably, adopting heavy dose of P, V, Mo, W mixing formula that common organophosphorus insecticides is poisoned has the excellent protection cell to avoid injury and toxic removal effect.
(3) P, V, Mo, W mixing formula use amount computational methods
In P, V, Mo, W mixing formula, metabolism takes place in the v element compound in human or animal body after, free vanadic acid radical ion VO
4 3-And the safe dose minimum of its esters, free vanadic acid radical ion VO in the salt of promptly same P, V, Mo, W molecular number
4 3-And the toxic and side effect maximum of its esters.So, when calculating design of mixture, generally need be with free vanadic acid radical ion VO
4 3-And the molecular amounts of its esters is that benchmark calculates.
Be example with metavanadic acid ammonia below, twice oral metavanadic acid ammonia adult's every day of body weight 50kg, consumption is 2 * 8mg/ day, with optimum molecular number proportioning V: P: Mo: W=1: calculate the consumption of other compound at 8.5: 8.5: 10:
The P element is established and is used Na
2HPO
4, molecular weight is 141.98;
The Mo element is established and is used Na
2MoO
42H
2O, molecular weight are 241.95;
The W element is established and is used Na
2WO
42H
2O, molecular weight are 329.85;
Metavanadic acid ammonia NH wherein
4VO
3Molecular weight is molecular number=2 * 8/116.99=0.1368mmol of 116.99,2 * 8mg=16mg, other element consumption in the mixing formula:
Na
2HPO
4Weight M
P=8.5 * 0.1368mmol * 141.98=165mg=2 * 82.5mg/ day;
Na
2MoO
42H
2O weight M
Mo=8.5 * 0.1368mmol * 241.95=281mg=2 * 140.5mg/ day;
Na
2WO
42H
2O weight M
W=10 * 0.1368mmol * 329.85=451mg=2 * 225.5mg/ day;
Use metavanadic acid ammonia NH
4VO
3, Na
2HPO
4, Na
2MoO
42H
2O, Na
2WO
42H
2O is that V, P, Mo, W element are that consumption every day of mixing formula is respectively: 2 * 8mg, 2 * 82.5mg, 2 * 140.5mg, 2 * 225.5mg.If using is not the mixing formula that contains V, P, Mo, four kinds of elements of W fully, then can finish getting final product by the molecular number proportioning calculating of aforementioned discussion.
That following table is represented is metavanadic acid ammonia NH
4VO
3, tungstate dihydrate acid sodium Na
2WO
42H
2O, Sodium Molybdate Dihydrate Na
2MoO
42H
2O, dibastic sodium phosphate Na
2HPO
4Share the result of treatment on various different cases.
By treatment experiment as can be known, the nutriment of this phosphorous vanadium, molybdenum and tungsten is at multiple disease, and, leukaemia smelly as diabetes, oral peculiar smell, pin, urinary calculus, gall stone and uremia all have significant treatment and mitigation.The invention has the beneficial effects as follows that can make with a kind of mixture with phosphorous vanadium, molybdenum and tungsten oxyacid and its esters, the manufacture process method is very simple, also can select the compound of the multiple valence state of phosphorus vanadium, molybdenum and tungsten to make, make the raw material source extensively.This nutriment has quicken to be eliminated the most of chemical substances of human body toxic side effect accumulating (comprising the chemical substance to the human body toxic side effect that most of bacteriums and viral metabolism produce) in vivo, reduce common paathogenic factor, thereby have the effect of direct prolongation human longevity.
The variation that is appreciated that a lot of details is possible, but therefore this do not run counter to scope and spirit of the present invention, and any person of an ordinary skill in the technical field all should be considered as not breaking away from the category of patent of the present invention to its suitable variation of doing.
Claims (7)
1. the nutriment of a phosphorous vanadium, molybdenum and tungsten is characterized in that: be to contain the common mixture of forming of phosphorus-containing compound, vanadium-containing compound, molybdate compound and Tungstenic compound; Or contain heteropoly acid and its esters that phosphorus vanadium, molybdenum and tungsten oxyacid and its esters form each other.
2. the nutriment of a kind of phosphorous vanadium, molybdenum and tungsten as claimed in claim 1 is characterized in that phosphorus-containing compound is the phosphoric acid or the phosphorous water soluble salt of+5 valencys.
3. the nutriment of a kind of phosphorous vanadium, molybdenum and tungsten as claimed in claim 1, it is characterized in that vanadium-containing compound be+5 ,+4 ,+3 ,+heteropoly acid or heteropolyacid salt that the water soluble compound of the vanadium of divalent attitude or complex compound or vanadium and other element form.
4. the nutriment of a kind of phosphorous vanadium, molybdenum and tungsten as claimed in claim 1, it is characterized in that molybdate compound be+6 ,+5 ,+heteropoly acid or heteropolyacid salt that the water soluble compound of the molybdenum of 4 valence states or complex compound or molybdenum and other element form.
5. the nutriment of a kind of phosphorous vanadium, molybdenum and tungsten as claimed in claim 1, it is characterized in that Tungstenic compound can be+6 ,+5 ,+heteropoly acid or heteropolyacid salt that the water soluble compound of the tungsten of 4 valence states or complex compound or tungsten and other element form.
6. the nutriment of a kind of phosphorous vanadium, molybdenum and tungsten as claimed in claim 1, it is characterized in that: the molecular number proportioning of each component of vanadium-containing compound, phosphorus-containing compound, molybdate compound and Tungstenic compound is V: P: Mo: W=1: (6～12): (6～12): (8～16).
7. as the nutriment of claim 1 or 6 described a kind of phosphorous vanadium, molybdenum and tungstens, it is characterized in that: the molecular number proportioning of each component of vanadium-containing compound, phosphorus-containing compound, molybdate compound and Tungstenic compound is V: P: Mo: W=1: 8.5: 8.5: 10.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910214447A CN101720937A (en) | 2009-12-30 | 2009-12-30 | Nutriment containing phosphorus, vanadium, molybdenum and tungsten |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910214447A CN101720937A (en) | 2009-12-30 | 2009-12-30 | Nutriment containing phosphorus, vanadium, molybdenum and tungsten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101720937A true CN101720937A (en) | 2010-06-09 |
Family
ID=42442963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910214447A Pending CN101720937A (en) | 2009-12-30 | 2009-12-30 | Nutriment containing phosphorus, vanadium, molybdenum and tungsten |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101720937A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2551828A1 (en) * | 2014-05-21 | 2015-11-23 | Oxolife S.L. | Food compositions comprising tungsten salts (VI) (Machine-translation by Google Translate, not legally binding) |
-
2009
- 2009-12-30 CN CN200910214447A patent/CN101720937A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2551828A1 (en) * | 2014-05-21 | 2015-11-23 | Oxolife S.L. | Food compositions comprising tungsten salts (VI) (Machine-translation by Google Translate, not legally binding) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105125610A (en) | Application of sunflower disc hydrolysis compound powder in preparing of medicine for curing or relieving high uric acid gout | |
| WO2011027301A1 (en) | Algae spirulina platensis preservation by natural honey | |
| CN105394351A (en) | Oligosaccharide chelated composite trace element mineral matter supplement and preparation method thereof | |
| Bartges et al. | Nutrition and lower urinary tract disease in cats | |
| HU226984B1 (en) | Medical and food products for treating diabetes mellitus and process for producing thereof | |
| CN101720937A (en) | Nutriment containing phosphorus, vanadium, molybdenum and tungsten | |
| CN102302502A (en) | Compound glycyrrhizin preparation and preparation method thereof | |
| Longo et al. | Succinyl-CoA: 3-ketoacid transferase (SCOT) deficiency in a new patient homozygous for an R217X mutation | |
| CN101904856A (en) | Application of 1,6-diphosphofructose and derivative thereof in preparing animal medical health care products | |
| CN107519219A (en) | A kind of compound pet kidney disease tablet and preparation method thereof | |
| WO2005041949A1 (en) | Composition for the treatment of dysfunctional energy metabolism syndrome | |
| CN101744123A (en) | Organic calcium supplement and preparation method and uses thereof | |
| CN105995119A (en) | High-copper feed for establishing HLD (hepatolenticular degeneration) animal model and preparation method of high-copper feed | |
| CN1732946B (en) | Pharmaceutical composition for preventing and treating poultry ascites | |
| CN108079035A (en) | A kind of hypoglycemic anti-inflammatory nutrient solution and preparation method thereof | |
| CN114376983B (en) | Natural extract composite granule suitable for high uric acid population | |
| Ajagun-Ogunleye et al. | Hypoglycemic and high dosage effects of bidens pilosa in type-1 diabetes mellitus | |
| CÎRŢÎNĂ et al. | Considerations on the Role of Mineral Substances in the Organism | |
| CN112755194B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN107441124A (en) | A kind of oral liquid for decreasing blood sugar and preparation method thereof | |
| Gajanayake | Nutrition in critical care | |
| CN107595829B (en) | A kind of composition for preventing and treating renal osteodystrophy | |
| DE102013008875B4 (en) | Process for enzymatic purine degradation | |
| CN108524592A (en) | A kind of prevention diabetic syndrome nutrient solution | |
| Afzaal et al. | THERAPEUTIC APPROACH IN THE MANAGEMENT OF PERITONEAL DIALYSIS; PLANT-BASED DIET AND ASSOCIATED PARAMETERS, A COMPREHENSIVE REVIEW |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100609 |